Recent Updates
Recently added Catalysts
PTCT Neutral Sentiment

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an...

Key Takeaway: PTC Therapeutics, Inc. announced the approval of inducement grants for nineteen new employees on October 23, 2024. The grants include stock options to purchase 13,690 shares and 20,250 restricted stock units (RSUs). These awards are part of the new hires' compensation and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $42.48 per share, and both stock options and RSUs will vest over four years contingent on continued employment.
Price reaction · baseline $41.4 (2024-10-24 close) · hit after-hours · 1 other PTCT headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • PTC Therapeutics is incentivizing new employees with stock options and RSUs.
  • The compensation package aims to attract talent in a competitive labor market.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
6.6%
average across 4 past catalysts
Lead asset
Ataluren
Phase 3 · Cystic Fibrosis

Full Press Release Details

WARREN, N.J. , Oct. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Oct. 23, 2024 , the company approved non-statutory stock options to purchase an aggregate of 13,690 shares of its common stock and 20,250 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to nineteen new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
The inducement grants were approved by PTC's Compensation Committee on Oct. 23, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $42.48 per share, the closing price of PTC's common stock on Oct. 23, 2024, the immediately preceding trading day. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.
For more information please contact:

Frequently Asked Questions

What stock options did PTC Therapeutics grant recently?

PTC Therapeutics granted 13,690 non-statutory stock options and 20,250 RSUs.

How many employees received stock options at PTC Therapeutics?

Nineteen new employees received the stock options and RSUs.

What is the exercise price of the stock options?

The exercise price is $42.48 per share, based on the closing stock price.

How long is the term for the stock options?

The stock options have a 10-year term from the grant date.

When do the RSUs vest for employees?

RSUs vest over four years, with 25% vesting each year on the anniversary.

Last updated: Oct 25, 2024